Acute respiratory distress syndrome – Treatment

Go back

Acute respiratory distress syndrome (ARDS) is a serious lung condition that demands urgent medical attention and comprehensive care. When fluid accumulates in the tiny air sacs of the lungs, oxygen cannot reach the bloodstream efficiently, leading to dangerously low oxygen levels throughout the body. Treatment focuses on supporting breathing, addressing the underlying cause, and preventing complications while the lungs heal.

How Medical Teams Approach ARDS Care

The primary goal when treating acute respiratory distress syndrome is to maintain adequate oxygen levels in the blood so that vital organs can continue functioning properly. Because ARDS typically develops as a complication of another serious illness or injury, healthcare providers must address both the lung damage and the condition that triggered it. Treatment strategies depend heavily on how severe the syndrome is, which underlying problem caused it, and the overall health status of each individual patient.[1]

ARDS affects approximately 200,000 people in the United States each year, and most patients require admission to an intensive care unit where specialized teams can monitor and support their breathing around the clock. The condition can worsen rapidly, sometimes within hours, making quick recognition and intervention essential for the best possible outcomes.[12]

There is currently no cure that can reverse ARDS once it develops. Instead, medical treatment is supportive, meaning it helps the body manage symptoms and gives the lungs time to heal on their own. With proper care, an estimated 60% to 75% of people who develop ARDS survive the condition, though recovery can be lengthy and challenging.[8]

⚠️ Important
ARDS is always a medical emergency. Most cases occur in people already hospitalized for another serious condition, but if someone who is not in a hospital develops severe shortness of breath, rapid breathing, or a bluish color to the lips or fingernails, they should go to the emergency department immediately or call emergency services. These symptoms indicate that the body is not getting enough oxygen, which can quickly become life-threatening.

Standard Treatment Methods for ARDS

The foundation of ARDS treatment is oxygen therapy. Because the damaged lungs cannot move enough oxygen into the bloodstream on their own, patients need supplemental oxygen delivered through various methods. The simplest approach involves delivering oxygen through tubes that rest in the nose or through a face mask. However, many patients with ARDS need more advanced breathing support.[11]

Mechanical ventilation is often necessary when oxygen levels remain dangerously low despite supplemental oxygen. A ventilator is a machine that helps a person breathe by pushing air into the lungs through a tube placed in the windpipe. This procedure, while potentially uncomfortable, is often life-saving. Healthcare providers use a specific strategy called low tidal volume ventilation, which means the ventilator delivers smaller breaths than normal. This approach has been proven to improve survival in ARDS by reducing additional damage to already injured lungs. The ventilator settings are carefully adjusted to maintain adequate oxygen while minimizing harm, typically targeting a tidal volume of about 6 milliliters per kilogram of ideal body weight.[16]

Another technique called positive end-expiratory pressure, or PEEP, is used with mechanical ventilation. PEEP keeps the airways from completely collapsing at the end of each breath out, which helps more of the lung stay open and functional. This allows better oxygen exchange without requiring dangerously high oxygen concentrations or excessive pressure that could further injure lung tissue.[5]

Some patients may benefit from noninvasive ventilation methods before requiring full mechanical ventilation. Bilevel positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) machines deliver air pressure through a face mask rather than a tube in the windpipe. These devices help keep airways open and can improve oxygen levels in less severe cases, though they do not work for everyone with ARDS.[11]

Fluid management is another crucial component of standard ARDS treatment. While patients need enough fluids to maintain blood pressure and organ function, too much fluid can worsen the accumulation of fluid in the lungs. Healthcare providers follow a conservative fluid strategy, carefully balancing the body’s fluid levels to avoid overload while ensuring adequate circulation to organs. This approach has been shown to improve outcomes and reduce the time patients spend on ventilators.[13]

Prone positioning involves turning patients onto their stomachs rather than keeping them on their backs. This simple but labor-intensive technique can dramatically improve oxygen levels in severe ARDS. When lying face-down, different parts of the lungs expand more effectively, and fluid redistributes in ways that improve gas exchange. Studies have shown that prone positioning can improve survival in patients with severe ARDS. Patients typically spend 16 hours or more per day in the prone position, with careful monitoring to prevent pressure sores and other complications.[13]

Identifying and treating the underlying cause of ARDS is essential for recovery. If a bacterial infection such as pneumonia or sepsis triggered the lung injury, appropriate antibiotics must be started quickly. If the cause was aspiration of stomach contents, preventing further aspiration is critical. When trauma or burns led to ARDS, managing those injuries becomes part of the overall treatment plan. Without addressing the root cause, the lungs cannot begin to heal even with optimal supportive care.[17]

Pain management and sedation are often necessary, especially for patients on mechanical ventilators. Being intubated and connected to a breathing machine can be uncomfortable and anxiety-provoking. Medications help keep patients comfortable and calm, which also allows them to tolerate the ventilator better. However, medical teams now aim to use the minimum amount of sedation necessary, as excessive sedation can prolong recovery and increase complications.[15]

Neuromuscular blocking agents are medications that temporarily paralyze muscles. In severe ARDS, these drugs may be used for short periods to help the ventilator work more effectively by preventing the patient from fighting against the machine. While this sounds frightening, patients receive sedation alongside these medications so they are not aware of being unable to move. The use of neuromuscular blockers must be carefully monitored and limited in duration to avoid prolonged muscle weakness.[13]

Corticosteroids are anti-inflammatory medications that may be used in some cases of ARDS. The rationale is that ARDS involves significant lung inflammation, and corticosteroids might reduce this inflammatory response. However, the evidence for their effectiveness is mixed. Some studies suggest potential benefits, particularly when started early in the disease course, while others show no clear advantage. Doctors must weigh the potential benefits against risks such as increased infection susceptibility and delayed wound healing when considering corticosteroid treatment.[17]

Inhaled pulmonary vasodilators such as nitric oxide may be tried in severe cases to improve oxygen levels. These medications work by relaxing blood vessels in the lungs, particularly in areas that are well-ventilated, which can improve the match between airflow and blood flow. While inhaled vasodilators can temporarily improve oxygenation, they have not been shown to reduce mortality or shorten time on the ventilator, so their use remains selective.[13]

Nutritional support becomes important as ARDS treatment continues. Patients on ventilators cannot eat normally, so nutrition is provided through tubes placed in the stomach or through intravenous lines. Adequate nutrition supports the body’s healing processes and helps maintain strength, though the optimal timing and composition of nutritional support in ARDS continues to be studied.[15]

Advanced and Emerging Therapies in Clinical Research

Beyond standard treatments, researchers are investigating various innovative approaches to improve outcomes for people with ARDS. Clinical trials test new medications, devices, and strategies that might someday become part of routine care. These studies typically progress through phases, with Phase I trials focusing primarily on safety, Phase II trials examining whether a treatment shows promise of effectiveness, and Phase III trials comparing new treatments against current standard care in larger groups of patients.[13]

One area of ongoing research involves alternative ventilation modes for patients who do not respond adequately to conventional mechanical ventilation. High frequency oscillatory ventilation uses very rapid, small breaths rather than the normal breathing pattern. The theory behind this approach is that the small tidal volumes might reduce lung injury while the rapid rate maintains gas exchange. However, large clinical trials have not demonstrated clear benefits from this strategy, and some studies even suggested potential harm. As a result, high frequency oscillatory ventilation remains primarily a research tool or last-resort option for the most severe cases of ARDS.[13]

Airway pressure release ventilation is another alternative ventilator mode being studied. This technique maintains a high level of pressure in the airways most of the time, with brief releases of pressure that allow exhalation. The goal is to keep more of the lung open continuously while allowing some spontaneous breathing efforts by the patient. Research continues to evaluate whether this mode offers advantages over conventional ventilation strategies for ARDS patients.[13]

Extracorporeal membrane oxygenation, commonly known as ECMO, represents the most advanced form of life support for severe ARDS. When mechanical ventilation cannot maintain adequate oxygen levels even with optimal settings, ECMO can temporarily take over some or all of the work of the lungs. During veno-venous ECMO (V-V ECMO), blood is removed from large veins, circulated through a machine that adds oxygen and removes carbon dioxide, then returned to the bloodstream. This allows healthcare providers to use very gentle ventilator settings that minimize further lung injury while the damaged lungs have time to heal.[13]

ECMO is highly complex and carries significant risks including bleeding, blood clots, and infection. It requires specialized centers with trained teams available around the clock. Despite these challenges, studies suggest that ECMO may improve survival for carefully selected patients with the most severe ARDS. Current research focuses on identifying which patients benefit most from ECMO, the optimal timing for initiating this therapy, and the best techniques for managing patients while on ECMO support. Clinical trials examining ECMO for severe ARDS have been conducted at specialized centers in the United States, Europe, and other regions worldwide.[13]

Researchers are exploring medications that might specifically target the underlying biological processes causing lung damage in ARDS. One area of investigation involves drugs that could reduce the excessive inflammatory response that characterizes ARDS. The challenge is that inflammation is part of the body’s normal defense mechanism, so completely blocking inflammation might increase infection risk. Scientists are working to identify therapies that can modulate rather than eliminate the inflammatory response, potentially reducing harm while preserving beneficial aspects of immunity.[13]

Some clinical trials are examining whether identifying specific subtypes of ARDS could allow more targeted treatments. Researchers have identified patterns suggesting that ARDS is not a single uniform condition but rather a syndrome that can result from different biological pathways. If healthcare providers could quickly identify which subtype a patient has, they might be able to select treatments more likely to help that individual. This concept of personalized or precision medicine in ARDS remains in early research stages but holds promise for the future.[13]

Mesenchymal stem cell therapy is being investigated in clinical trials for severe ARDS. These cells have properties that might reduce inflammation and promote tissue repair. In laboratory studies and small clinical trials, mesenchymal stem cells showed some promise. Researchers are now conducting larger Phase II and Phase III trials to determine whether these cells actually improve outcomes when given to ARDS patients. These studies are taking place at medical centers in several countries, with careful monitoring for both potential benefits and unexpected side effects.[13]

Efforts to develop improved diagnostic tools are also underway. Better methods to predict who will develop ARDS, assess its severity, or monitor response to treatment could help guide therapy decisions. Some research focuses on identifying blood biomarkers—measurable substances in the blood that indicate specific disease processes. If reliable biomarkers could be found, they might help clinicians determine which treatments to use or when a patient is improving enough to reduce support.[13]

⚠️ Important
Participation in clinical trials is voluntary and involves potential risks as well as potential benefits. Patients and families considering clinical trial enrollment should discuss thoroughly with healthcare providers what the trial involves, what is known and unknown about the experimental treatment, and what alternatives exist. Not all ARDS patients are eligible for clinical trials, as studies typically have specific inclusion and exclusion criteria designed to answer particular research questions safely.

Most Common Treatment Methods

  • Oxygen therapy and breathing support
    • Supplemental oxygen delivered through nasal tubes or face masks for milder cases
    • Mechanical ventilation with low tidal volume strategy (approximately 6 mL/kg ideal body weight) to reduce lung injury
    • Positive end-expiratory pressure (PEEP) to keep airways open and improve oxygen exchange
    • Noninvasive ventilation using BiPAP or CPAP machines in selected cases
    • Extracorporeal membrane oxygenation (ECMO) for the most severe cases not responding to conventional ventilation
  • Positioning strategies
    • Prone positioning (lying face-down) for 16 or more hours daily in severe ARDS to improve oxygen levels and survival
  • Fluid management
    • Conservative fluid strategy to avoid overload while maintaining adequate organ perfusion and blood pressure
  • Medications
    • Antibiotics or other antimicrobials to treat underlying infections such as pneumonia or sepsis
    • Sedatives and pain medications to improve comfort, especially for patients on mechanical ventilators
    • Neuromuscular blocking agents for short-term use in severe cases to improve ventilator effectiveness
    • Corticosteroids in selected cases to reduce inflammation, though benefits remain uncertain
    • Inhaled pulmonary vasodilators like nitric oxide to temporarily improve oxygenation in severe cases
  • Supportive care
    • Nutritional support through feeding tubes or intravenous nutrition
    • Treatment of underlying conditions that triggered ARDS (such as sepsis, trauma, pancreatitis)
    • Prevention of complications including blood clots, pressure sores, and hospital-acquired infections

Recovery and Long-Term Outlook After ARDS

Recovery from ARDS is often a long process that continues well after leaving the intensive care unit. The time spent on a ventilator and the severity of illness both influence how long recovery takes. Some people regain most or all of their previous lung function, while others experience lasting effects. Common challenges during recovery include continued shortness of breath, muscle weakness, fatigue, and difficulty returning to normal activities.[18]

Many ARDS survivors need supplemental oxygen for weeks or months after hospitalization. As the lungs heal, oxygen needs typically decrease, though some individuals require long-term oxygen therapy. Healthcare providers monitor lung function and oxygen levels during follow-up visits to determine when oxygen can be reduced or discontinued.[10]

Physical weakness is nearly universal after critical illness with ARDS. Prolonged bed rest, medications, and the severity of illness all contribute to muscle loss and deconditioning. Physical therapy and rehabilitation programs help patients regain strength and endurance. The recovery process requires patience, as it may take months to rebuild physical capacity. Some people benefit from formal pulmonary rehabilitation programs that combine exercise training, breathing exercises, education, and support specifically designed for people recovering from serious lung conditions.[19]

Psychological effects of surviving ARDS can be significant. Many survivors experience anxiety, depression, or post-traumatic stress disorder (PTSD) related to their ICU experience. Memories of being unable to breathe, the discomfort of mechanical ventilation, or gaps in memory during sedation can be distressing. Healthcare providers now recognize these psychological impacts as important aspects of ARDS recovery. Counseling, support groups connecting ARDS survivors, and treatment for mental health conditions are all part of comprehensive recovery care.[19]

Some survivors experience cognitive changes after ARDS, including problems with memory, attention, or thinking clearly. These changes may be temporary or may persist longer-term. The causes are complex and may include the effects of low oxygen levels, medications, inflammation, and the stress of critical illness. Cognitive rehabilitation and accommodations at work or home may help people manage these challenges during recovery.[18]

Regular follow-up care is essential after ARDS. Healthcare providers monitor lung function, oxygen levels, and overall recovery. They can identify and address complications or lingering problems. Follow-up visits also provide opportunities to adjust treatments, recommend rehabilitation services, and provide support for patients and families navigating the recovery process.[18]

Not everyone survives ARDS. Despite advances in treatment, mortality remains close to 40% even with optimal care. Age, severity of ARDS, the underlying cause, and other health conditions all influence outcomes. For those who do not survive, ensuring comfort and supporting families through difficult decisions about goals of care are important aspects of compassionate medical practice.[8]

Ongoing Clinical Trials on Acute respiratory distress syndrome

  • Study on Anticoagulation Strategies with Heparin, Enoxaparin, and Argatroban for Patients with Respiratory or Circulatory Failure on ECMO Support

    Recruiting

    1 1 1 1
    Austria
  • Study of High-Dose Vitamin C (Ascorbic Acid) Compared to Placebo in Patients with Sepsis and Acute Respiratory Distress Syndrome (ARDS) in Intensive Care

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on Dornase Alfa and Placebo to Reduce ARDS in Ventilated Trauma Patients in ICU

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on [68Ga]FAPI-46 to Detect Fibroblast Activity in Patients with Non-Resolving Acute Respiratory Distress Syndrome (ARDS) in the ICU

    Recruiting

    1 1 1
    Investigated diseases:
    The Netherlands
  • Study on Imlifidase for Patients with Severe ANCA-Associated Vasculitis and Lung Bleeding

    Recruiting

    1 1 1
    Investigated drugs:
    Germany
  • Study of inhaled aprotinin for treatment of moderate to severe acute respiratory distress syndrome

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain
  • Study on Premedication with Ketamine or Fentanyl for Patients with Respiratory Distress Syndrome Receiving Surfactant Treatment

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland
  • Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Italy
  • Study on Anakinra for Patients with Non-COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study on the Effects of Metoprolol in Patients with Acute Respiratory Distress Syndrome (ARDS)

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

References

https://my.clevelandclinic.org/health/diseases/15283-acute-respiratory-distress-syndrome-ards

https://www.mayoclinic.org/diseases-conditions/ards/symptoms-causes/syc-20355576

https://www.nhlbi.nih.gov/health/ards

https://www.lung.org/lung-health-diseases/lung-disease-lookup/ards

https://www.ncbi.nlm.nih.gov/books/NBK436002/

https://www.nhs.uk/conditions/acute-respiratory-distress-syndrome/

https://www.aafp.org/pubs/afp/issues/2012/0215/p365.html

https://www.yalemedicine.org/conditions/ards

https://www.merckmanuals.com/home/quick-facts-lung-and-airway-disorders/respiratory-failure-and-acute-respiratory-distress-syndrome/acute-respiratory-distress-syndrome-ards

https://www.lung.org/lung-health-diseases/lung-disease-lookup/ards/ards-treatment-and-recovery

https://www.nhlbi.nih.gov/health/ards/treatment

https://my.clevelandclinic.org/health/diseases/15283-acute-respiratory-distress-syndrome-ards

https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04572-w

https://www.yalemedicine.org/conditions/ards

https://www.mayoclinic.org/diseases-conditions/ards/diagnosis-treatment/drc-20355581

https://www.ncbi.nlm.nih.gov/books/NBK436002/

https://emedicine.medscape.com/article/165139-treatment

https://www.nhlbi.nih.gov/health/ards/living-with

https://ardsalliance.org/living-with-ards-a-guide-for-patients-and-caregivers/

https://my.clevelandclinic.org/health/diseases/15283-acute-respiratory-distress-syndrome-ards

https://www.lung.org/lung-health-diseases/lung-disease-lookup/ards/ards-treatment-and-recovery

https://healthy.kaiserpermanente.org/health-wellness/health-encyclopedia/he.acute-respiratory-distress-syndrome-ards.abn1432

https://site.thoracic.org/advocacy-patients/patient-resources/acute-respiratory-distress-syndrome

https://myhealth.alberta.ca/Health/aftercareinformation/pages/conditions.aspx?hwid=abs2060

https://www.yalemedicine.org/conditions/ards

FAQ

What is the main cause of acute respiratory distress syndrome?

Sepsis is the most common cause of ARDS, occurring when a serious infection in the lungs or other organs triggers widespread inflammation. Other frequent causes include pneumonia, aspiration of stomach contents into the lungs, major trauma or burns, COVID-19, pancreatitis, blood transfusions, inhalation injuries from smoke or chemical fumes, and drug overdoses. ARDS typically develops within hours to days of the triggering event.

How long does it take to recover from ARDS?

Recovery from ARDS varies considerably among individuals. The time spent on a ventilator and the severity of illness both influence recovery duration. Many survivors need weeks to months of rehabilitation to regain strength and lung function. Some people recover most of their previous lung capacity, while others experience lasting effects including shortness of breath, the need for supplemental oxygen, and reduced exercise tolerance. Physical, cognitive, and psychological recovery may continue for many months after leaving the hospital.

What is the survival rate for ARDS patients?

With appropriate treatment in intensive care settings, an estimated 60% to 75% of people who develop ARDS survive the condition. This means mortality ranges from approximately 25% to 40%, with rates varying based on factors including age, severity of ARDS, the underlying cause, and other health conditions. Severe ARDS has higher mortality rates, approaching 50% in some studies. Survival has improved over recent decades due to advances in supportive care, particularly the use of lung-protective ventilation strategies.

Will I need a ventilator if I have ARDS?

Most people with ARDS require mechanical ventilation because supplemental oxygen alone cannot maintain adequate blood oxygen levels. The ventilator helps breathing by pushing air into the lungs through a tube placed in the windpipe. Healthcare providers use specific settings designed to protect the lungs from further damage while they heal. Some patients with milder ARDS may be managed with noninvasive breathing support using masks instead of tubes, but this works for only a subset of cases. In the most severe situations, advanced support like ECMO may be necessary when conventional ventilation is insufficient.

Can ARDS cause permanent lung damage?

ARDS can result in lasting lung effects for some survivors. While many people recover substantial lung function, others experience persistent shortness of breath, reduced exercise capacity, or the need for ongoing oxygen therapy. Some patients develop lung scarring (fibrosis) during the healing process, particularly if they progressed to the fibrotic stage of ARDS or required prolonged mechanical ventilation. The extent of permanent damage varies widely among individuals and depends on factors including the severity of initial injury, the duration of illness, and the presence of complications during treatment.

🎯 Key Takeaways

  • ARDS affects about 200,000 Americans annually and demands immediate intensive care treatment to prevent life-threatening oxygen deprivation
  • Low tidal volume mechanical ventilation is the only proven treatment to reduce ARDS mortality and remains the cornerstone of respiratory support
  • Prone positioning—simply turning patients face-down for extended periods—dramatically improves oxygen levels and survival in severe cases
  • There is no medication that cures ARDS; treatment focuses on supporting breathing and treating the underlying cause while lungs heal naturally
  • ECMO represents the most advanced life support option for the most severe cases, temporarily replacing lung function when ventilators alone cannot maintain adequate oxygenation
  • Recovery extends far beyond hospital discharge, with many survivors facing months of physical rehabilitation and potential psychological effects including PTSD
  • Clinical trials continue exploring innovative therapies including stem cell treatments and precision medicine approaches tailored to ARDS subtypes
  • Survival rates reach 60% to 75% with modern intensive care, though severe ARDS still carries mortality approaching 50% despite optimal treatment